+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Premenstrual Syndrome Treatment Market by Drug Type, Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021819
  • Report
  • January 2020
  • Region: Global
  • 241 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • ABBVIE INC.
  • AstraZeneca plc.
  • BASF Corporation
  • Bayer AG
  • Eli Lilly And Company
  • GlaxoSmithKline Plc.
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026. Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability. Lifestyle changes are anticipated to help relieve PMS symptoms. However, based on the severity of symptoms, different types of drugs such as analgesics, antidepressants, and diuretics are used.



The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.

The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type market is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of major four geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type
  • Analgesics
  • Antidepressants
  • Oral Contraceptives & Ovarian Suppression Agents
  • Others

By Type
  • Prescription
  • OTC

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • ABBVIE INC.
  • AstraZeneca plc.
  • BASF Corporation
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly And Company
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Pfizer Inc
  • Shionogi Inc

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Teva Pharmaceutical Industries Ltd.
  • Allergan PLC
Frequently Asked Questions about the Global Premenstrual Syndrome Treatment Market

What is the estimated value of the Global Premenstrual Syndrome Treatment Market?

The Global Premenstrual Syndrome Treatment Market was estimated to be valued at $1129.0 million in 2018.

What is the growth rate of the Global Premenstrual Syndrome Treatment Market?

The growth rate of the Global Premenstrual Syndrome Treatment Market is 3.8%, with an estimated value of $1516.0 million by 2026.

What is the forecasted size of the Global Premenstrual Syndrome Treatment Market?

The Global Premenstrual Syndrome Treatment Market is estimated to be worth $1516.0 million by 2026.

Who are the key companies in the Global Premenstrual Syndrome Treatment Market?

Key companies in the Global Premenstrual Syndrome Treatment Market include ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S and Shionogi Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ABBVIE INC.
  • AstraZeneca plc.
  • BASF Corporation
  • Bayer AG
  • Eli Lilly And Company
  • GlaxoSmithKline Plc.

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Key Findings
2.2.1. Top Investment Pockets
2.2.2. Top Player Positioning, 2018
2.3. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Forces Shaping Premenstrual Syndrome Treatment Industry/Market
3.2.1. Moderate Power of Suppliers
3.2.2. Moderate Threat of New Entrants
3.2.3. Low Threat of Substitution
3.2.4. Moderate Competitive Rivalry
3.2.5. Moderate Bargaining Power of Buyers
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Increase In Prevalence of Pms
3.3.1.2. Growth In Awareness For Pms Therapeutics
3.3.1.3. Surge In Healthcare Expenditure Worldwide
3.3.2. Restraint
3.3.2.1. Poor Demand In Under Developed Countries
3.3.3. Opportunities
3.3.3.1. Growth Opportunities In Emerging Markets
3.3.3.2. Higher Number of Unmet Needs For Treatment of Pms
3.3.4. Impact Analysis
Chapter 4: Premenstrual Syndrome Treatment Market, By Drug Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Analgesics
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Antidepressants
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Oral Contraceptives & Ovarian Suppression Agents
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Others
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
Chapter 5: Premenstrual Syndrome Treatment Market, By Type.
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Prescription
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Otc
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
Chapter 6: Premenstrual Syndrome Treatment Market, By Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Drug Stores & Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Analysis, By Country
6.4. Online Pharmacies
6.4.1. Market Size And Forecast
6.4.2. Market Analysis, By Country
Chapter 7: Premenstrual Syndrome Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.1.2. U.S. Premenstrual Syndrome Treatment Market, By Type
7.2.2.1.3. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.2.2. Canada
7.2.2.2.1. Canada Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.2.2. Canada Premenstrual Syndrome Treatment Market, By Type
7.2.2.2.3. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico Premenstrual Syndrome Treatment Market, By Drug Type
7.2.2.3.2. Mexico Premenstrual Syndrome Treatment Market, By Type
7.2.2.3.3. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel
7.2.3. North America Market Size And Forecast, By Drug Type
7.2.4. North America Premenstrual Syndrome Treatment Market, By Type
7.2.5. North America Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.1.2. Germany Premenstrual Syndrome Treatment Market, By Type
7.3.2.1.3. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.2. France
7.3.2.2.1. France Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.2.2. France Premenstrual Syndrome Treatment Market, By Type
7.3.2.2.3. France Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.3. UK
7.3.2.3.1. UK Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.3.2. UK Premenstrual Syndrome Treatment Market, By Type
7.3.2.3.3. UK Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.4. Italy
7.3.2.4.1. Italy Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.4.2. Italy Premenstrual Syndrome Treatment Market, By Type
7.3.2.4.3. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.5. Spain
7.3.2.5.1. Spain Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.5.2. Spain Premenstrual Syndrome Treatment Market, By Type
7.3.2.5.3. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type
7.3.2.6.2. Rest of Europe Premenstrual Syndrome Treatment Market, By Type
7.3.2.6.3. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel
7.3.3. Europe Market Size And Forecast, By Drug Type
7.3.4. Europe Premenstrual Syndrome Treatment Market, By Type
7.3.5. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.1.2. Japan Premenstrual Syndrome Treatment Market, By Type
7.4.2.1.3. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.2. China
7.4.2.2.1. China Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.2.2. China Premenstrual Syndrome Treatment Market, By Type
7.4.2.2.3. China Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.3. Australia
7.4.2.3.1. Australia Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.3.2. Australia Premenstrual Syndrome Treatment Market, By Type
7.4.2.3.3. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.4. India
7.4.2.4.1. India Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.4.2. India Premenstrual Syndrome Treatment Market, By Type
7.4.2.4.3. India Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.5. South Korea
7.4.2.5.1. South Korea Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.5.2. South Korea Premenstrual Syndrome Treatment Market, By Type
7.4.2.5.3. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type
7.4.2.6.2. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type
7.4.2.6.3. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel
7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
7.4.4. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type
7.4.5. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.1.2. Brazil Premenstrual Syndrome Treatment Market, By Type
7.5.2.1.3. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.2.2. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type
7.5.2.2.3. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.3.2. South Africa Premenstrual Syndrome Treatment Market, By Type
7.5.2.3.3. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA Premenstrual Syndrome Treatment Market, By Drug Type
7.5.2.4.2. Rest of LAMEA Premenstrual Syndrome Treatment Market, By Type
7.5.2.4.3. Rest of LAMEA Premenstrual Syndrome Treatment Market, By Distribution Channel
7.5.3. LAMEA Market Size And Forecast, By Drug Type
7.5.4. LAMEA Premenstrual Syndrome Treatment Market, By Type
7.5.5. LAMEA Premenstrual Syndrome Treatment Market, By Distribution Channel
Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Astrazeneca Plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. Basf Corporation
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Bayer Ag.
8.4.1. Company Overview
8.4.2. Operating Business Segments
8.4.3. Product Portfolio
8.4.4. Business Performance
8.5. Dr. Reddy's Laboratories Ltd
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Eli Lilly And Company.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Glaxosmithkline Plc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. H. Lundbeck A/S
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Pfizer Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Shionogi Inc.
8.10.1. Company Overview
8.10.2. Operating Business Segments
8.10.3. Product Portfolio
8.10.4. Business Performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ABBVIE INC.
  • AstraZeneca plc.
  • BASF Corporation
  • Bayer AG
  • Eli Lilly And Company
  • GlaxoSmithKline Plc.
According to the report, titled, 'Premenstrual Syndrome Treatment Market, by Drug Type, Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global premenstrual syndrome treatment market size was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, growing at a CAGR of 3.7% from 2019 to 2026.

Premenstrual syndrome (PMS) is a condition that affects emotional behavior and physical health of women during or few days before their menstrual cycle. PMS often leads to acne, tender breasts, bloating, irritability, and mood swings , which could be managed by lifestyle changes or drug treatment. Medication such as analgesics, antidepressants, oral contraceptives and ovarian suppression agents are generally used to manage PMS.

The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to rise in demand for PMS treatment medication across the globe and an increase in awareness related to PMS. Surge in number of target population is further anticipated to boost the premenstrual syndrome treatment market growth during the forecast period. According to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms. In addition, growth in demand for premenstrual therapeutics in developing countries further creates opportunities for the premenstrual syndrome treatment market. However, unknown etiology and pathophysiology of PMS and adverse effects associated with off label drugs are anticipated to hamper the market growth.

By drug type, the market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment and is estimated to show the same dominance during the forecast period, owing to preferable use of Nonsteroidal anti-inflammatory (NSAIDs) as first line treatment in management of PMS.

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs, increase in awareness of online pharmacies, and rise in number of internet users.

Key Findings of the Study
By drug Type, the analgesics segment held more than three forth share in the global market in 2018.
By distribution channel, the online providers segment exhibits fastest growth and is expected to grow at a CAGR of 4.9% from 2019 to 2026.
By distribution channel, the drug stores & retail pharmacies segment held the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
Region wise, Asia-Pacific is expected to experience a significant growth, registering a CAGR of 5.1% during the forecast period.
North America accounted for approximately one-half of the global premenstrual syndrome treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the rise in higher adoption of premenstrual syndrome treatment medication, rise in PMS treatment awareness among patients, and large number of target population, with wide availability of PMS treatment therapeutics in this region. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to growing number of target population with an the increase in the adoption of premenstrual syndrome treatment medication in the region.
Note: Product cover images may vary from those shown
  • ABBVIE INC.
  • AstraZeneca plc.
  • BASF Corporation
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly And Company
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Shionogi Inc.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...